Please login to the form below

Not currently logged in
Email:
Password:

European recommendation for Galvus' monotherapy license

CHMP issues positive opinion for Novartis' diabetes drug

Novartis has won backing from European regulatory advisers for a monotherapy licence for its type II diabetes drug Galvus (vildagliptin).

This would allow the drug to be used on its own in patients whose diabetes is inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.

The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on extending the drug's current licence as a dual oral therapy.

At the moment it can only be used in combination with metformin, a sulphonylurea (if metform is inappropriate) or a thiazolidinedione in patients with insufficient glycaemic control.

CHMP positive opinions are normally passed as full European approval within three months, and would give a further boost to Galvus, which is also marketed in Europe under the brand names Jalra and Xiliarx.

The diabetes drug recently extended its licence in Europe, winning approval to treat type two diabetic patients with either moderate or severe renal impairment.

19th December 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics